Champions Oncology Inc (CSBR)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $65.49M
Last updated: Nov 17, 2026 at 10:50 AM ET
Champions Oncology Inc (CSBR) Earnings: Report Dates and Results
Champions Oncology (CSBR) is expected to report earnings on Dec 14, 2026. In the quarter ended Jul 31, 2026, Champions Oncology reported EPS of -$0.03, below the -$0.01 estimate. It beat the EPS estimate in 4 of the 8 most recent quarters that had an estimate.
Earnings
Performance (10Y)
Next Report
CSBR has an expected report date of Dec 14, 2026.
CSBR Earnings Call
The latest CSBR earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 31 quarters below that had an estimate, CSBR beat 13, missed 15 and matched 3. Revenue for the quarter ended Jul 31, 2026 was $15.23M, up 8.9% from $13.99M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Jul 31, 2026 | -$0.03 | -$0.01 | N/A | -200.00% | Miss | -250.0% | N/A | N/A | Sep 10, 2026 | $15.23M |
| Apr 30, 2026 | -$0.05 | -$0.05 | N/A | 0.00% | In line | N/A | N/A | N/A | Jul 27, 2026 | $13.84M |
| Jan 31, 2026 | -$0.02 | $0.08 | N/A | -125.13% | Miss | -106.1% | 1 | 1 up, 0 down | Mar 12, 2026 | $16.56M |
| Oct 31, 2025 | $0.06 | $0.01 | N/A | +500.00% | Beat | +20.0% | 1 | 0 up, 1 down | Dec 15, 2025 | $15.04M |
| Jul 31, 2025 | $0.02 | -$0.01 | -$0.01 - -$0.01 | +300.00% | Beat | -81.8% | 1 | 0 up, 1 down | Sep 15, 2025 | $13.99M |
| Apr 30, 2025 | -$0.07 | $0.06 | N/A | -216.67% | Miss | -800.0% | 1 | 0 up, 1 down | Jul 23, 2025 | $12.36M |
| Jan 31, 2025 | $0.33 | -$0.01 | -$0.01 - -$0.01 | N/A | N/A | N/A | 1 | 1 up, 0 down | Mar 11, 2025 | $17.04M |
| Oct 31, 2024 | $0.05 | $0.01 | $0.01 - $0.01 | +400.00% | Beat | N/A | 1 | 1 up, 0 down | Dec 11, 2024 | $13.49M |
| Jul 31, 2024 | $0.11 | -$0.03 | -$0.03 - -$0.03 | +466.67% | Beat | N/A | 1 | 0 up, 0 down | Sep 11, 2024 | $14.06M |
| Apr 30, 2024 | $0.01 | -$0.16 | -$0.16 - -$0.16 | +106.25% | Beat | N/A | 1 | 0 up, 0 down | Jul 18, 2024 | $14.00M |
| Jan 31, 2024 | -$0.16 | -$0.06 | N/A | -166.67% | Miss | N/A | 1 | 1 up, 0 down | Mar 12, 2024 | $12.02M |
| Oct 31, 2023 | -$0.15 | -$0.16 | N/A | +6.25% | Beat | -1600.0% | 2 | 0 up, 0 down | Dec 12, 2023 | $11.57M |
| Jul 31, 2023 | -$0.16 | -$0.10 | -$0.10 - -$0.10 | -60.00% | Miss | N/A | 1 | 0 up, 0 down | Sep 13, 2023 | $12.56M |
| Apr 30, 2023 | -$0.19 | -$0.12 | -$0.17 - -$0.08 | -58.33% | Miss | N/A | 2 | 0 up, 0 down | Jul 24, 2023 | $13.07M |
| Jan 31, 2023 | -$0.16 | -$0.01 | -$0.06 - -$0.01 | N/A | N/A | -328.6% | 2 | 0 up, 0 down | Mar 15, 2023 | $12.77M |
| Oct 31, 2022 | $0.01 | $0.02 | N/A | -50.00% | Miss | -66.7% | 2 | 0 up, 0 down | Dec 13, 2022 | $14.28M |
| Jul 31, 2022 | -$0.01 | $0.02 | N/A | -150.00% | Miss | -200.0% | 2 | 0 up, 0 down | Sep 8, 2022 | $13.74M |
| Apr 30, 2022 | -$0.03 | $0.03 | $0.02 - $0.03 | -200.00% | Miss | N/A | 2 | 0 up, 0 down | Jul 21, 2022 | $12.88M |
| Jan 31, 2022 | $0.07 | $0.04 | N/A | +75.00% | Beat | 0.0% | 2 | 0 up, 0 down | Mar 15, 2022 | $13.19M |
| Oct 31, 2021 | $0.03 | $0.02 | N/A | +50.00% | Beat | +29900.0% | 2 | 0 up, 0 down | Dec 13, 2021 | $11.79M |
| Jul 31, 2021 | $0.01 | $0.01 | $0.01 - $0.01 | 0.00% | In line | 0.0% | 1 | 0 up, 0 down | Sep 13, 2021 | $11.25M |
| Apr 30, 2021 | -$0.04 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Jul 22, 2021 | $10.56M |
| Jan 31, 2021 | $0.07 | $0.01 | $0.00 - $0.01 | +600.00% | Beat | +40.0% | 3 | N/A | Mar 11, 2021 | $10.81M |
| Oct 31, 2020 | $0.00 | $0.01 | -$0.01 - $0.01 | -99.00% | Miss | -99.7% | 3 | N/A | Dec 14, 2020 | $10.12M |
| Jul 31, 2020 | $0.01 | -$0.03 | N/A | +133.33% | Beat | N/A | 1 | N/A | Sep 14, 2020 | $9.55M |
| Apr 30, 2020 | -$0.14 | $0.02 | $0.01 - $0.02 | -800.00% | Miss | N/A | 2 | N/A | Jul 27, 2020 | $8.75M |
| Jan 31, 2020 | $0.05 | $0.03 | $0.02 - $0.03 | +66.67% | Beat | +400.0% | 3 | N/A | Mar 12, 2020 | $9.01M |
| Oct 31, 2019 | $0.03 | $0.01 | -$0.04 - $0.01 | +200.00% | Beat | 0.0% | 3 | N/A | Dec 16, 2019 | $7.63M |
| Jul 31, 2019 | -$0.05 | $0.02 | N/A | -350.00% | Miss | -200.0% | 1 | N/A | Sep 16, 2019 | $6.74M |
| Apr 30, 2019 | -$0.01 | $0.03 | $0.03 - $0.03 | -133.33% | Miss | N/A | 1 | N/A | Jul 15, 2019 | $7.72M |
| Jan 31, 2019 | $0.01 | $0.03 | $0.03 - $0.04 | -66.67% | Miss | N/A | 3 | N/A | Mar 18, 2019 | $6.43M |
| Oct 31, 2018 | $0.03 | $0.05 | N/A | -40.00% | Miss | N/A | N/A | N/A | Dec 17, 2018 | $6.69M |
| Jul 31, 2018 | $0.05 | $0.01 | $0.01 - $0.01 | +400.00% | Beat | N/A | 1 | N/A | Sep 13, 2018 | $6.22M |
| Apr 30, 2018 | -$0.04 | -$0.04 | -$0.04 - -$0.03 | 0.00% | In line | N/A | 2 | N/A | Jul 26, 2018 | $4.92M |
| Jan 31, 2018 | -$0.01 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 15, 2018 | $5.08M |
| Oct 31, 2017 | -$0.01 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Dec 7, 2017 | $5.20M |
| Jul 31, 2017 | -$0.06 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Sep 14, 2017 | $5.03M |
| Apr 30, 2017 | -$0.15 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Jul 27, 2017 | $3.72M |
| Jan 31, 2017 | -$0.11 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 16, 2017 | $3.56M |
| Oct 31, 2016 | -$0.05 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 29, 2016 | $4.46M |
Annual EPS
EPS for the fiscal year ended Apr 30, 2026 was $0.01, down 97.6% from the year before. It was -$0.56 for the year ended Apr 30, 2017, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Apr 30, 2026 | $0.01 | -97.6% |
| Apr 30, 2025 | $0.42 | N/A |
| Apr 30, 2024 | -$0.46 | N/A |
| Apr 30, 2023 | -$0.35 | -537.5% |
| Apr 30, 2022 | $0.08 | N/A |
| Apr 30, 2021 | $0.04 | N/A |
| Apr 30, 2020 | -$0.11 | -237.5% |
| Apr 30, 2019 | $0.08 | N/A |
| Apr 30, 2018 | -$0.12 | N/A |
| Apr 30, 2017 | -$0.56 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 1,800 words across 3 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 1,795 | 3 | |
| 2026Q2 | Jun 30, 2026 | 2,310 | 5 | |
| 2026Q1 | Mar 31, 2026 | 2,321 | 6 | |
| 2025Q4 | Dec 31, 2025 | 2,860 | 5 | |
| 2025Q3 | Sep 30, 2025 | 4,413 | 6 | |
| 2025Q2 | Jun 30, 2025 | 1,915 | 4 | |
| 2025Q1 | Mar 31, 2025 | 1,987 | 4 | |
| 2024Q4 | Dec 31, 2024 | 2,938 | 4 |
2026Q3 Earnings Call
Opening remarks
Robert Brainin CEO Good afternoon, and thank you for joining us for our third quarter fiscal 2026 earnings call. I'm Rob Brainin, CEO of Champions Oncology, and I'm joined today by our CFO, David Miller. Before we begin, I'll remind everyone that today's remarks may include forward-looking statements. Actual results may differ materially, and additional information can be found in our filings with the SEC. Before I walk through the quarter, let me briefly highlight 3 key takeaways. First, we delivered another quarter of strong operational performance, including record services revenue and our third consecutive quarter of positive adjusted EBITDA. Second, while quarterly revenue can fluctuate in our business, we remain on track for full year revenue growth and full year positive adjusted EBITDA while continuing to invest in both our data platform and our discovery therapeutics subsidiary. And third, we're beginning to see early momentum in our data business, including new deals closed during the quarter and additional revenue expected in the fourth quarter. Overall, we're pleased with the progress we're making as we scale the core services business while building the longer-term growth opportunities in data and drug discovery. Turning to the quarter in more detail. We delivered another quarter of record services revenue, underscoring the strength of our core translational oncology services platform and the resilience of our customer relationships. Our PDX Bank remains a true differentiator in the market. And as customer budgets stabilize, we continue to see bookings convert into revenue. I also want to thank our operations team who delivered this growth without material additions to headcount. That reflects the operating leverage in our model and our ability to expand margins as we scale. As we've said repeatedly, this is a somewhat lumpy business. Quarterly revenue can fluctuate depending on the timing of study progression and completion. During the quarter, we saw strong conversion of previously booked work, including some backlog from prior quarters, which benefited revenue in the period. Looking ahead, we would expect revenue to normalize somewhat as studies move through their various stages. That said, the underlying demand for our services remains healthy, and our focus continues to be on expanding the pipeline of future work through increased commercial engagement. This quarter, despite strong services performance, our year-over-year revenue showed a slight decline due to the large data deal we closed in the third quarter last year. Importantly, our services revenue came close to fully offsetting that comparison.
Frequently Asked Questions About CSBR
When is Champions Oncology's next earnings date?
Champions Oncology's next earnings report is expected for Dec 14, 2026.
Did CSBR beat earnings estimates last quarter?
No. Champions Oncology reported EPS of -$0.03 for the quarter ended Jul 31, 2026, below the -$0.01 estimate by 200.00%.
How often does CSBR beat earnings estimates?
Champions Oncology beat the EPS estimate in 4 of the 8 most recent quarters that had an estimate, with an average surprise of +140.61%.
CSBR pages: Overview, Earnings, Financials, Valuation, Competitors